CORGENIX MED CORP (CONX)

0.26
0.00 0.38
OTC
Prev Close 0.27
Open 0.27
Day Low/High 0.26 / 0.28
52 Wk Low/High 0.00 / 0.00
Volume 264.11K
Exchange OTC
Shares Outstanding 54.97M
Market Cap 14.51M
Div & Yield N.A. (N.A)

Latest News

Corgenix Signs Memorandum Of Understanding Regarding Settlement Of Litigation And Announces Plan To Adjourn Special Meeting To December 10

Corgenix Signs Memorandum Of Understanding Regarding Settlement Of Litigation And Announces Plan To Adjourn Special Meeting To December 10

Corgenix Medical Corporation (OTCQB: CONX.OB) (the "Company") announced today that it has entered into a memorandum of understanding with plaintiffs' counsel in the consolidated Nevada putative shareholder class action...

Corgenix Announces Preliminary Revenue And Net Loss Results For Quarter Ended September 30, 2014

Corgenix Announces Preliminary Revenue And Net Loss Results For Quarter Ended September 30, 2014

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at...

Corgenix Provides Update On Ebola Test Kit NIH Grant

Corgenix Provides Update On Ebola Test Kit NIH Grant

Ebola virus outbreaks tend to occur every few years and then go away rapidly.

Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award At AACC 2014 Meeting

Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award At AACC 2014 Meeting

Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in...

Corgenix Joins Strategic Partners, Presents Science At AACC Meeting And Clinical Lab Expo 2014

Corgenix Joins Strategic Partners, Presents Science At AACC Meeting And Clinical Lab Expo 2014

Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American ...

Corgenix Signs Technology Transfer, Product Development Agreement With Mellitus LLC For Gestational Diabetes Test

Corgenix Signs Technology Transfer, Product Development Agreement With Mellitus LLC For Gestational Diabetes Test

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass.

Corgenix, Research Group Announce NIH Grant To Advance Work On Ebola Rapid Diagnostic Test Kit

Corgenix, Research Group Announce NIH Grant To Advance Work On Ebola Rapid Diagnostic Test Kit

Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.

Corgenix Announces CE Mark Notification For TxBCardio™ Assay

Corgenix Announces CE Mark Notification For TxBCardio™ Assay

Corgenix Medical Corporation (OTC BB: CONX.OB) announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio™ Assay.

Corgenix Reports Third Quarter Fiscal 2014 Financial Results

Corgenix Reports Third Quarter Fiscal 2014 Financial Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its third-quarter Form 10-Q and reported its financial results.

Corgenix To Host Conference Call To Discuss Third Quarter Results

Corgenix To Host Conference Call To Discuss Third Quarter Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, May 15, 2014, at 4:00 p.

Corgenix, Tulane And Viral Hemorrhagic Fever Consortium Publish Promising Results From Lassa Fever Trial

Corgenix, Tulane And Viral Hemorrhagic Fever Consortium Publish Promising Results From Lassa Fever Trial

A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of...

Corgenix And Research Partners To Expand Ebola Virus Testing Capabilities In Sierra Leone

Corgenix And Research Partners To Expand Ebola Virus Testing Capabilities In Sierra Leone

An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus.

Corgenix Board Of Directors Announces Exploration Of Strategic Alternatives

Corgenix Board Of Directors Announces Exploration Of Strategic Alternatives

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company’s Board of Directors has decided to explore strategic alternatives to ...

Corgenix Reports Second Quarter Fiscal 2014 Financial Results

Corgenix Reports Second Quarter Fiscal 2014 Financial Results

Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results.

Corgenix To Host Conference Call To Discuss Second Quarter Results

Corgenix To Host Conference Call To Discuss Second Quarter Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.

Corgenix Announces Filing Of 510(k) Premarket Notification For FDA Clearance Of TxBCardio™ Assay

Corgenix Announces Filing Of 510(k) Premarket Notification For FDA Clearance Of TxBCardio™ Assay

Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.

Corgenix To Launch New Hepcidin-25 Product At The American Society Of Hematology Annual Meeting

Corgenix To Launch New Hepcidin-25 Product At The American Society Of Hematology Annual Meeting

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA ...

Corgenix Inks Collaborative Diagnostic Test Development Deal With Zalgen Labs

Corgenix Inks Collaborative Diagnostic Test Development Deal With Zalgen Labs

Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Zalgen Labs, a biotechnology...

Corgenix Reports First Quarter Fiscal 2014 Financial Results

Corgenix Reports First Quarter Fiscal 2014 Financial Results

Corgenix Medical Corporation (OTCBB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results.

Corgenix Files Concurrent De Novo 510(k) Pre-Market Notification For FDA Clearance Of Its Hyaluronic Acid (HA) Test Kit

Corgenix Files Concurrent De Novo 510(k) Pre-Market Notification For FDA Clearance Of Its Hyaluronic Acid (HA) Test Kit

Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today it has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.

Study: Aspirin Ineffective In 20 Percent Of Heart Disease Patients

Study: Aspirin Ineffective In 20 Percent Of Heart Disease Patients

A major new study conducted in Ireland found that 20 percent of patients with established heart disease were not adequately protected by aspirin.

Corgenix To Host Conference Call To Discuss First Quarter Results

Corgenix To Host Conference Call To Discuss First Quarter Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, November 14, 2013, at 4:00 PM EST to discuss the Company’s ...

Corgenix Announces Diagnostic Test Development Partnership With Health Diagnostic Laboratory, Inc.

Corgenix Announces Diagnostic Test Development Partnership With Health Diagnostic Laboratory, Inc.

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory , Inc.

Corgenix Reports Fiscal 2013 Financial Results

Corgenix Reports Fiscal 2013 Financial Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal year Form 10-K and reported financial results.

Corgenix To Host Conference Call To Discuss Fiscal 2013 Results

Corgenix To Host Conference Call To Discuss Fiscal 2013 Results

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company’s financial ...

Corgenix Medical Corporation Announces New AtherOx® (Oxidized LDL Technology) License And Cooperation Agreement

Corgenix Medical Corporation Announces New AtherOx® (Oxidized LDL Technology) License And Cooperation Agreement

Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx ® License and Cooperation Agreement with Eiji Matsuura,...

Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility

Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility

Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.